(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
‘Trip of suffering’: Gaza evacuee details 24-hour journey to South Africa - 2German men need approval for stays abroad under military service law
- 3Netflix Faces Wider Fallout After Italy Court Orders Refunds, Price Cuts
- 4Does physics say that free will doesn't exist?
- 5High-Suggested Broilers For Your Homes
- Israel strikes south Lebanon after first direct talks in decades
- The Ursid meteor shower will be the last of the year, peaking just before Christmas: What to know and how to watch
- Flying without a Real ID? That'll soon cost you $45, TSA says.
- New research reveals urban raccoons across the US show early signs of domestication
- Israel approves death penalty law for Palestinians convicted of attacks
- One ant for $220: the new frontier of wildlife trafficking
- Instructions to Construct an Organization While Chasing after a Web-based Degree
- Solar storms have influenced our history – an environmental historian explains how they could also threaten our future
- Eurasian cargo hub expands to capture Europe-Asia freight flows
